Ocala Research Institute, Inc.

Ocala, Florida 34480

3 studies enrolling now · 13 studies all time

What they study most

Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Cardiovascular Disease, Coronary Artery Disease, Coronary Disease, Coronary Heart Disease (CHD), Dyslipidemia, Early Breast Cancer, Heart Failure, High Cardiovascular Risk, Hospitalized Elderly, Lung Cancer

Studies at this site

• OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events — Recruiting now
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure — Recruiting now
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — Recruiting now
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke — Completed
• Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD — Running, not enrolling
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors — Completed
• Phase III Acute Coronary Syndrome — Stopped early
• A Trial of an Oral Nutritional Supplement in Older Hospitalized Patients - NOURISH Study — Completed
• Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer — Completed
• A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN) — Withdrawn before enrolling
• The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention — Completed
• Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Completed